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A B S T R A C T
The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a
global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute
respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are
now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly
conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is
increased compared to the general population because of an overall impairment of immune system typical of
autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive
drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to
consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this
review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to
treat RA in this particular scenario, in order to optimize the current approach to RA patients.
1. Introduction
In December 2019 a new type of pneumonia supported by a novel
member of the coronoviridae family named SARS-CoV-2 (severe acute
respiratory coronavirus 2 syndrome) developed from Wuhan Province
in China [1]. Phylogenetic analysis demonstrated that this is a different
virus with ~80% nucleotide identity with SARS-CoV-1 [2]. The disease
caused by SARS-CoV-2 is characterized by dry cough, fever, dyspnea
and fatigue, accompanied by lymphopenia [3–6]. In more severe cases
(apparently up to 15–20% of infected patients) the picture may become
more complicated by the onset of interstitial pneumonia with alveolar
damage, which clinically can lead to severe Acute Respiratory Distress
Syndrome (ARDS) and even death [7]. Since the initial outbreak, the
epidemic has had a rapid global spread worldwide which led the World
Health Organization (WHO) to declare the disease now called COVID-
19 a Public Health Emergency of International Concern on 30th Jan-
uary 2020 and a pandemic on 11th March 2020. The epidemiological
picture is constantly evolving, and data updated as of March 17th count
159 countries involved with more than 185,000 cases and 7500 con-
firmed deaths [8].
In this context of growing health emergency, clarifying the re-
lationship between COVID-19 and the population of fragile patients
suffering from immune-rheumatological diseases is absolutely crucial.
On the one hand, the rapid and uncontrolled spread of the epidemic can
clearly generate even more concerns in rheumatic patients, which are
intrinsically characterized by an increased infectious risk due to the
disease itself and to the iatrogenic effect of immunosuppressive agents
such as corticosteroids and synthetic or biological disease-modifying
drugs [9]. On the other hand, the growing knowledge about the pa-
thogenesis of SARS-CoV-2 infection is leading to the introduction of
drugs commonly used for the treatment of rheumatoid arthritis (RA)
even for the management of more complex cases of COVID-19. Chlor-
oquine and hydroxychloroquine have now been permanently included,
alongside antiviral drugs, in protocols for the treatment of COVID-19
pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers
seems to be very promising for the management of the massive cytokine
storm associated to the development of the typical lung damage and the
consequent ARDS occurring in the most aggressive patterns of SARS-
CoV infection [11].
Therefore, waiting for observational data on the incidence of
COVID-19 in rheumatological patients, the best strategy to manage
immune-rheumatological diseases during this emergency period is still
far to be clear. The purpose of this review is to provide an overview on
viral infectious risk in RA patients, with a particular focus on the
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knowledge about the current new pandemic and the use of anti-rheu-
matic drugs in this context of health emergency.
2. The pathophysiology of COVID-19 infection
Coronaviruses are the largest viruses with a positive-sense single-
stranded-RNA genome. The host immune response is by one side es-
sential for the resolution of COVID-19 infection, but it can also be
crucial for the pathogenesis of major clinical manifestations of the
disease. The angiotensin-converting enzyme 2 (ACE2) has been iden-
tified as the host cell-surface receptor for SARS-CoV2 envelope spike
glycoprotein [12]. ACE2 is a type I membrane protein expressed on
cells in the kidney, heart, gastrointestinal tract, blood vessels, and,
importantly, lung AT2 alveolar epithelial cells, which are particularly
prone to viral infection [13]. SARS-CoV-2 infection leads to the
downregulation of ACE2 expression, thus resulting in excessive pro-
duction of angiotensin II by the related enzyme ACE. It has been sug-
gested that the stimulation of type 1a angiotensin II receptor (AGTR1A)
increases pulmonary vascular permeability, thus potentially explaining
the increased lung damage when the expression of ACE2 is decreased
[14]. Due to this mechanism of action, it has been postulated that
subjects with diabetes mellitus or hypertension using ACE-inhibitors or
angiotensin receptor blockers may have an increase of both the risk of
infection and the severity of COVID-19 [15]. As only scarce evidence
supports this hypothesis, the European Society of Cardiology recently
published a position statement that strongly recommends continuing
these treatments despite the current epidemic [16]. An additional point
to be clarified is also the role of the genetic predisposition for an in-
creased risk of SARS-CoV-2 infection due to ACE2 polymorphisms that
have been linked to hypertension, diabetes mellitus, and cerebral
stroke, especially in Asian populations [15].
The viral RNA genome is released into the cytoplasm, and the RNA
is uncoated to allow translation of the two polyproteins, transcription of
the sub-genomic RNAs and replication of the viral genome [17]. Pro-
gression to ARDS is associated with the upregulation of pro-in-
flammatory cytokines and chemokines, known as Cytokines Release
Syndrome (CRS), with a pattern very similar to that of secondary
haemophagocytic lymphohistiocytosis (sHLH). In adults, sHLH is an
under-recognized, hyperinflammatory syndrome characterized by a
massive and fatal hypercytokinaemia with multiorgan failure, most
commonly triggered by viral infections [18,19]. Main clinical features
of sHLH include unremitting fever, hyperferritinaemia and cytopenias,
and pulmonary involvement (including ARDS) occurring in approxi-
mately 50% of patients [20]. A cytokine profile resembling sHLH has
been reported in most severe COVID-19 infections, characterized by
increased levels of a number of cytokines (interleukin-1β [IL-1β], IL-2,
IL-6, IL-7, IL-8, tumor necrosis factor-α [TNF]) and chemokines (CXC-
chemokine ligand 10 [CXCL10] and CC-chemokine ligand 2 [CCL2])
[21,22]. The management of this cytokine storm is one of the major
unmet needs regarding COVID-19 infection.
3. Is the risk of viral infection increased in RA patients?
The relationship between RA and infectious diseases is very complex
and can be interpreted in two different directions. On the one hand, in
fact, the potential role of external microorganisms in producing acute
and chronic arthritis in the form of either the direct colonization of the
joints by the pathogen or the aberrant autoimmune reaction produced
by the host response to the infection is well known [23,24]. Few studies
have investigated a potential link between respiratory viral infections
and the development of RA [25] and in particular a Korean study re-
ported parainfluenza and coronavirus to be associated with the number
of incident RA [26]. In addition, in patients with overt inflammatory
arthritis, infections are a major concern as they can contribute to dis-
ease flares [27–29]. On the other hand, RA patients carry a documented
increased risk of infection compared with the general population. A
population-based study by Doran and colleagues compared two mat-
ched groups of 609 patients with or without RA showing that RA pa-
tients had a significantly higher risk of serious (RR 1.53, 95% CI
1.41–1.65) and hospitalized (RR 1.88, 95% CI 1.71–2.07) infections
[30]. Similarly, a prospective cohort study conducted on 2108 patients
with inflammatory polyarthritis reported a 2- to 4-fold increased risk of
hospitalized infection compared to healthy population [31]. This trend
is primarily the result of a general impairment of the immune system
typical of all autoimmune disorders and strictly dependent on the de-
gree of disease activity. In fact, it has been demonstrated by an analysis
conducted in 16,242 RA patients from the US CORRONA registry that
each 0.6 unit increase in Disease Activity Score 28 (DAS28) corre-
sponded to a 25% increased rate of infections requiring hospitalization
(Incident rate ratio [IRR] 1.25, p = .03) and a 4% increased rate of
outpatient infections (IRR 1.04, p = .01) [32]. In addition, a sub-
sequent report from the same registry showed that the risk of serious
infections increased progressively from patients achieving clinical re-
mission to those achieving low (adjusted IRR 1.69, 95% CI 1.32–2.15)
or moderate (adjusted IRR 1.30, 95% CI 1.09–1.56) disease activity,
demonstrating the importance of maintaining a good disease control in
order to reduce infectious complications [33].
Another important determinant of infectious risk is the presence of
comorbidities, which very often complicate the course of RA [34].
Diabetes mellitus, cardiovascular diseases, renal failure, interstitial lung
disease, and chronic obstructive pulmonary disease (COPD) are all
concomitant disorders associated with an increased incidence of in-
fections in RA [27,35].
Finally, RA can also be complicated by infections caused by the
iatrogenic effect of immunosuppressive therapies, which will be dis-
cussed in detail in the next section.
4. The impact of drugs for rheumatic diseases on viral infections:
what do we know?
4.1. Corticosteroids and NSAIDs
It has now been more than 70 years that corticosteroids (CS) are
pivotal for RA management and their role as remission inducer and
bridging therapy for the management of disease flare has recently been
renewed by the latest update of EULAR recommendations for RA
treatment [36]. Even though CS efficacy in rapidly suppressing in-
flammation during RA initial course or flares is well recognized [37],
their downside is the broad spectrum of adverse events, including se-
vere infections and the high risk of developing comorbidities further
increasing the risk of infection [27,38]. Although RCTs conducted in
the past with CS showed no higher risk of infections in RA patients
[39–41], cohort and case-control studies reported increased rates of
overall infections in RA patients treated with CS, according to a dose-
dependent fashion [42]. The majority of these infectious events are of
bacterial etiology, but RA patients receiving CS exhibit a greater risk of
developing even viral infections. As an example, a 2012 retrospective
cohort-study demonstrated an increased risk of Herpes Zoster infections
with an incidence rate of 8.54 cases per 1000 patient-years in CS
treated population [29].
Thus, CS on the one hand inhibit the immune response and delay
the clearance of the pathogen, while on the other hand they suppress
the host inflammatory response, which in the case of viral infections of
the respiratory tract is the major responsible for lung damage and oc-
currence of ARDS [43]. The latter represented the rational for the
widely use of CS for the management of Middle East respiratory syn-
drome (MERS)-CoV [44] and SARS-CoV [45] outbreaks, both histolo-
gically characterized by lung inflammation and diffuse alveolar damage
[46]. However, evidence from the literature points to a predominantly
negative effect of CS in the management of this type of infection. A
2019 systematic review and meta-analysis including ten observational
studies (n= 6548) conducted in influenza reported increased mortality
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(risk ratio [RR] 1.75, 95% CI 1.3–2.4; p = .0002),
increased rate of secondary bacterial or fungal infection (RR 2·0,
95% CI 1·0–3·8; p = .04), and longer stay in an intensive care unit
(mean difference 2.1, 95% CI 1.2–3.1; p < .0001) in patients receiving
CS [47]. Moreover, a review exploring treatments for ARDS, including
six studies with a total of 574 patients, concluded that insufficient
evidence exists to recommend CS treatment [48]. Overall, no clear
reason exists to expect that patients with COVID-19 infection will
benefit from CS, and they might be more likely to be harmed with such
therapy [49]. In fact, current interim guidance from WHO on clinical
management of COVID-19 infection advises against the use of CS unless
indicated for another reason [10].
The role of NSAIDs in the course of viral infections is still con-
troversial. Ibuprofen has been demonstrated to induce an over-
expression of ACE2 when used in diabetic rats [50] and this effect might
theoretically increase the susceptibility and worsen the clinical course
of COVID-19 infection in treated patients [15]. In addition, the use of
both NSAIDs and acetaminophen could be associated with a masking of
the fever rise during COVID-19, resulting in a delay in diagnosis and
proper management of the infection.
4.2. csDMARDs
The most comprehensive analysis of infectious risk in patients
treated with csDMARDs is a retrospective, longitudinal study of a po-
pulation-based RA cohort using an administrative database including a
total of 27,710 individuals with RA and providing 162,710 person-years
of follow-up [51]. Use of csDMARDs without corticosteroids was asso-
ciated with a small decrease in mild infection risk (adjusted rate ratio
[RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not
associated with increased serious infection risk (adjusted RR 0.92, 95%
CI 0.85–1.0). Similarly, another retrospective analysis conducted on
1993 patients from a claim database demonstrated a slightly reduced
risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95%
CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI
0.62–0.89) [52]. A recent systematic review and meta-analysis of the
literature confirmed the lack of an increased risk of infection in patients
receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these
reports provided no data on the risk of stratified infection by pathogen.
4.3. bDMARDs
The risk of infection observed in RA patients treated with bDMARDs
is generally considered slightly higher (from 1.5- up to 2-fold) com-
pared with csDMARDs [27,54]. This evidence recurred in most RCTs
[55] and observational registry studies [56–58] and was confirmed by a
recent meta-analysis which showed that this risk is progressively in-
creasing in relation to the use of bDMARDs at higher than re-
commended dosages [59]. Following the results of comparative meta-
nalyses and real-life studies, abatacept is accepted as the safest
bDMARD in terms of infectious risk [60,61].
Data focused on viral respiratory infections in bDMARD cohort are
still very limited. The incidence of influenza-like infections observed in
a cohort of 159 Italian patients treated with bDMARDs during the in-
fluenza season 2009–2010 was higher than the value reported in a wide
sample of Italian population in the same period, even though no im-
portant complications or hospitalizations have been reported [62].
Overall, post-marketing experience is relatively reassuring that anti-
TNF treated patients may not be at any specifically increased risk of
influenza and that severe adverse outcomes, including death, do not
appear to be exceedingly frequent [63].
4.4. tsDMARDs
The overall risk of serious and opportunistic infections observed
with Janus Kinase (JAK) inhibitors in RA patients is roughly
comparable with bDMARDs [64,65], although these early years of to-
facitinib and baricitinib use have raised the issue of an increased risk of
Herpes Zoster virus (HZV) infections [66]. Data from tofacitinib pooled
population enrolled in RCTs showed an HZV incidence rate of 4.0 per
100 patient-years (with greater incidence in geographic area with high
HZV endemicity), doubling the rates of RA patients not receiving JAKis
[67]. A similar picture has also been observed in the overall develop-
ment program of baricitinib, with an incidence rate of 3.2 cases per
patient-years [68]. The subsequent real-life experience from US claim
databases revealed that the risk of HZV was higher in patients receiving
tofacitinib compared to those treated with abatacept (aHR 2.01 (95% CI
1.40; 2.88) [69], and the risk of serious hospitalized HZV infection is 2-
fold higher versus all bDMARDs [70]. Older age, female sex, pre-
dnisone>7.5 mg/day, prior infection, and greater number of hospi-
talizations were associated with increased HZV risk, whereas vaccina-
tion was associated with a lower risk [71]. More recent reports from
RCTs conducted with novel JAK-1 selective inhibitors upadacitinib and
filgotinib have basically confirmed the same trend, suggesting that the
increase in HZV infections can be considered as a class effect of JAKis
[72,73]. Although the exact mechanism by which HZV reactivation
occurs in the context of JAK inhibition is unclear, the downregulation of
both cell-mediated immunity and innate antiviral signaling through
type I and II interferons (IFN) is likely to be involved [74].
Currently, no data are available on the risk of respiratory virus in-
fections carried by JAK inhibitors.
5. The management of COVID-19: a room for anti-rheumatic
drugs?
Currently, vaccines and approved targeted therapeutics for the
treatment of the new SARS-CoV-2 infection are still lacking and the
management of COVID-19 is only supportive, even though a multitude
of compounds are now under investigation for the treatment of this
emerging disease [75]. The need to urgently identify an effective ap-
proach to manage COVID-19 led to the strategy of testing the efficacy of
the existing antiviral drugs commonly used for other viral infections. In
particular, considering the similarity between SARS-CoV-2 and other
Betacoronavirus associated with previous epidemics as SARS-CoV and
MERS-Cov, the same drugs used with controversial results for these
conditions (interferon, ribavirin, and lopinavir-ritonavir) have been
considered even for COVID-19 [76]. Anecdotal cases have demon-
strated the ability of lopinavir-ritonavir to significantly reduce viral
load and improve disease outcome [77]. In addition, remdesivir, an
adenosine analogue currently under development for the management
of Ebola virus infection [78], has been recently recognized as a pro-
mising antiviral therapy against a wide spectrum of RNA viruses [79]
and showed good preliminary in vitro results in the control of SARS-
CoV-2 infection [80]. Consequently, lopinavir-ritonavir and remdesevir
are currently the only anti-viral drugs included in the more severe case
management protocols of COVID-19 [10]. Recent reports described the
potential role of human monoclonal antibodies that bind the cor-
onavirus spike receptor binding domain, leading to the neutralization of
SARS-CoV2 capability to interact with human target cells [81,82].
However, at the moment these can only be considered as potential
treatment options for the future, but they are obviously not available
for the management of the current pandemic.
Beyond the use of specific anti-viral products, many drugs com-
monly used in the treatment of RA have been proposed as possible
therapies for COVID-19 as a consequence of the increased knowledge
about the pathophysiology of the infection (Table 1).
5.1. Chloroquine/hydroxychloroquine
Chloroquine and hydroxychloroquine are widely used anti-malarial
drugs with well-known immunomodulatory properties that have ex-
tended their use to several immuno-rheumatological diseases including
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RA [83]. The ability of chloroquine to produce an anti-viral effect has
been known since the late 1960s [84]. Several mechanisms by which
the drug is able to interfere with the growth and spread of different
viruses (including SARS coronavirus) have been demonstrated in in vitro
studies [85], even though the subsequent in vivo experience was con-
troversial [86,87].
At clinically admissible concentrations chloroquine is able to in-
crease the endosomal pH required for virus/cell fusion, to inhibit the
toll-like receptor activity, and to interfere with terminal glycosylation
of the cellular receptor ACE 2 [88–90]. All these functions may nega-
tively influence the virus-receptor binding, resulting in a potential ef-
fect of the drug on both entry and post-entry stages of the SARS CoV
infection. As a consequence, chloroquine has recently been included in
at least 10 randomized controlled trials currently ongoing in China,
where it is tested for the treatment of COVID-19 under various com-
bination protocols with the anti-viral drugs mentioned above [91]. In-
terim results from more than 100 patients have demonstrated that
chloroquine is superior to the control treatment in improving lung
imaging findings, inhibiting the exacerbation of pneumonia, promoting
a virus negative conversion, and shortening the disease course at dif-
ferent levels of severity [92]. More recently, hydroxychloroquine was
demonstrated to be more 3-times more potent than chloroquine in an in
vitro study based on pharmacokinetic models (PBPK). An oral loading
dose of 400 mg twice daily, followed by a maintenance dose of 200 mg
given twice daily for 4 days seems to be the best option for the man-
agement of SARS-CoV-2 infection [93].
5.2. IL-6 and IL-1 blockers
As already described, ARDS occurring in most severe case of COVID-
19 infection is mainly produced by the massive release of pro-in-
flammatory mediators (CRS) associated with viral replication and lung
injury, leading to multiorgan failure [22]. Moreover, the high levels of
these cytokines have been reported to be inversely related to the ab-
solute lymphocytes count, with surviving T-cells functionally exhausted
[94]. Since an effective immune response against viral infections de-
pends on the activation of cytotoxic T cells, CRS might be associated
with a decreased viral clearance, contributing to COVID-19 worsening.
IL-6 and IL-1 play a pivotal role in this hyperinflammatory condition,
suggesting the potential use of their blockers as treatment option for
SARS-CoV2 related interstitial pneumonia. Data from a phase 3 RCT of
IL-1 blockade (anakinra) in sepsis showed significant survival benefit in
patients with hyperinflammation, without increased adverse events
[95]. A small retrospective study on 21 patients affected by severe
COVID-19 demonstrated that tocilizumab improved CT scan abnorm-
alities and oxygen saturation, and normalized CRP levels and
lymphocytes count in most of the patients [96]. A multicentre RCT of
tocilizumab (IL-6 receptor blocker licensed for both RA and cytokine
release syndrome) has been approved in China and is currently ongoing
in patients with COVID-19 pneumonia and elevated IL-6 levels
(ChiCTR2000029765) and a phase II study has been approved by the
Italian Regulatory Drug Agency (AIFA) and will enrol 330 patients with
pneumonia and early respiratory failure, with 1-month mortality re-
duction as primary outcome (TOCIVID-19). Moreover, the company
that produces the second marketed IL-6 inhibitor sarilumab recently
announced its intention to undertake a study with a similar design [97].
The identification of a unique definition of CRS during COVID-19
infection is crucial to better customize the management of critical pa-
tients. The presence of a large area of lung injury (≥50%) with de-
creased levels of CD4 and CD8 T-lymphocytes (lower than 50% of
minimum normal range), and increased levels of IL-6 in peripheral
blood have been recognized as the greatest risk factors of CRS in a
retrospective analysis of 11 critically pneumonia Chinese patients in-
fected with COVID-19 [98]. Increasing ferritin level and erythrocyte
sedimentation rate or decreasing platelet counts would be additional
parameters potentially useful to discriminate patients requiring im-
munosuppressive treatment [22].
5.3. TNF inhibitors
As previously described, SARS-CoV infection is associated with a
downregulation of ACE2 expression coupled with an increased activity
of the renin-angiotensin system responsible for lung injury [14].
Moreover, the viral spike protein is able to induce a TNF-α-con-
verting enzyme (TACE)-dependent shedding of the ACE2 ectodomain,
crucial for the penetration of the virus into the cell [99]. Since this
process seems to be strictly coupled to TNFα production, it has been
postulated that the use of TNF inhibitors may be effective in reducing
both SARS-CoV2 infection and the consequent organ damage [100]. As
a result, a study evaluating adalimumab in COVID-19 infection has
recently been registered in the Chinese Clinical Trial Registry
(ChiCTR2000030089).
5.4. Janus kinase inhibitors
As previously described in detail, SARS-CoV-2 enters targeted cells
through receptor-mediated endocytosis [12]. Some of the identified
regulators of clathrin-mediated endocytosis are members of the numb-
associated kinase (NAK) family, such as AP2-associated protein kinase 1
(AAK1) and cyclin G-associated kinase (GAK) [101]. Inhibition of AAK1
may stop the access of the virus into lung cells and also the intracellular
assembly of virus particles [102]. Of 47 AAK1 blockers approved for
Table 1
Potential role of anti-rheumatic drugs in COVID-19 infection.
PROS CONS
Chloroquine Anti-viral effect (increase of endosomal pH required for virus/cell fusion, inhibition of toll-like
receptor activity, interference with terminal glycosylation of the cellular receptor ACE 2)
–
Hydroxychloroquine
IL-6 inhibitors Treatment of cytokine storm manifestations during ARDS Lack of definite criteria to identify patients to be
treated
Potential community-acquired pneumonia due to
immunosuppression
Baricitinib Interference with viral penetration into the cell by blocking NAK-mediated endocytosis Impairment of IFN anti-viral response
Treatment of cytokine storm manifestations during ARDS Increased risk of secondary HZV infections
TNF-inhibitors Interference with viral penetration into the cell Slight increase in viral infection risk
NSAIDs – Facilitation of viral penetration by overexpression
of ACE2
Delay in diagnosis due to fever masking
Corticosteroids – Increased risk of viral infection
Increased mortality and risk of secondary bacterial
or fungal infection
ACE2 = angiotensin converting enzyme 2, ARDS = acute respiratory distress syndrome, NAK = numb-associated kinase; HZV = Herpes Zoster virus,
IFN = interferon, NSAIDs = nonsteroidal anti-inflammatory drugs.
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medical use, 6 inhibit AAK1 with high affinity. These include oncologic
agents such as erlotinib, sunitinib, ruxolitinib, and fedratinib, which
have all been demonstrated to inhibit infection of cells by Dengue virus,
Ebola virus, and respiratory syncytial virus [103]. Unfortunately, all
these compounds are able to produce adequate NAK inhibition only at
doses significantly higher than those normally used in clinical practice
and therefore potentially toxic for the patient [104,105]. Conversely,
the JAK inhibitor baricitinib is able to effectively inhibit AAK1 and GAK
at the plasma concentration obtained with the approved dosage for the
treatment of RA (2 to 4 mg daily) [106]. Moreover, as a selective in-
hibitor of JAK 1 and 2, baricitinib is also able to produce an important
dampening of host inflammatory response due to CRS (including IL-6
and interferon gamma) responsible for the more severe forms of in-
terstitial pneumonia during COVID-19 [107,108]. Finally, the minimal
interaction of baricitinib with the relevant CYP drug-metabolising en-
zymes makes the drug a possible candidate for inclusion in combination
protocols with antiviral drugs such as lopinavir/ritonavir and re-
mdesivir [109]. Interestingly, tofacitinib shows no detectable inhibition
of AAK1 [104], whereas currently no data are available on the possible
effect of other JAK inhibitors approved or tested for RA (such as upa-
dacitinib or filgotinib) in relation to coronavirus infection. Un-
expectedly, the only clinical trial evaluating the potential role of cla-
thrin-mediated endocytosis blockade in the management of COVID-19
is currently ongoing with ruxolitinib (ChiCTR2000029580).
On the other side, IFN is one of the most potent innate immune
responses to prevent viral replication during the early phases of infec-
tion [110]. The activation of transcription through JAK/STAT signaling
pathway by IFNs leads to the upregulation of several interferon sti-
mulated genes which have the ability to rapidly kill viruses within in-
fected cells [111]. Almost all viruses have developed strategies to
combat the effects of type 1 and type 3 IFNs by blocking the IFN sig-
naling pathway [112] and viral encoded factors able to antagonize the
JAK/STAT pathway are crucial determinants of virulence [113]. In
particular, Influenza A viruses disrupt JAK/STAT signaling by reducing
the expression of the IFN receptor and by directly inhibiting IFN sig-
naling [114]. As a consequence, JAK/STAT blockade generated by
baricitinib certainly produces an impairment of IFN-mediated anti-viral
response, with a potential facilitating effect on the progression of SARS-
CoV2 infection at the moment not yet better quantified.
In conclusion, evidence of the possible use of baricitinib in the
treatment of COVID-19 infection remains highly controversial and
further studies are warranted to better clarify its potential role in the
treatment of more serious cases of viral pneumonia.
6. Conclusions
The COVID-19 epidemic represents a health emergency that is in-
evitably affecting the management of a complex disease such as RA
[115,116]. As a chronic autoimmune inflammatory disorder, RA carries
a higher infectious risk than the general population. The use of syn-
thetic and biologic disease-modifying drugs is associated with a po-
tential further increase in the incidence of serious infections, but the
poor control of RA disease activity is an even greater infectious risk
factor. Thus, RA patients should be encouraged to continue their
treatment even during COVID-19 outbreak. In our opinion, this strategy
is reasonable as it aims to prevent disease flares that can contributes to
increase patient burden, disability, poor quality of life, and healthcare
use [117]. In addition, the discontinuation of ongoing treatments could
lead to the need to introduce CS as bridging therapy, which may further
increase the risk of viral infection, as well as being inappropriate for the
management of SARS-CoV2 interstitial pneumonia.
Chloroquine and hydroxychloroquine are currently included in the
treatment protocol for the management of COVID-19 infections and
might be useful to prevent or mitigate the course of infection in patients
with RA taking them as csDMARDs. The use of IL-6 inhibitors as toci-
lizumab or sarilumab seems to be promising for the management of
most critical cases of interstitial pneumonia complicated by CRS, but
the identification of definite criteria to discriminate patients to be
treated with these compounds is still under debate. Finally, although
baricitinib has the potential to affect SARS-CoV2 penetration into pul-
monary epithelial cells, major concerns remain about the inhibition of
IFNs activity which could be detrimental in the course of viral infection.
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